Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer? Baker SC, Mason AS, Southgate J. Eur Urol 2020 Nov 14. pii: S0302-2838(20)30866.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Baker SC, Mason AS, Southgate J. Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer? Eur Urol 2020 Nov 14. pii: S0302-2838(20)30866.
PMID: 33203550